BioCentury | Oct 24, 2020
Finance

Oct. 23 Quick Takes: RA Capital’s $461M new fund; plus venture rounds for Sirnaomics, 3D Medicines, Zhaoke, Orbus, Araris

...and undisclosed series A investors.Orbus tops off series A, adds von Emster to boardBay Area-based Orbus Therapeutics Inc....
...btov Partners and existing investors Redalpine, VI Partners and Schroder Adveq also invested. BC Staff Araris Biotech AG Orbus Therapeutics Inc. 3D...
BioCentury | Oct 3, 2016
Clinical News

Eflornithine: Phase III started

...3-week cycle plus oral lomustine every 6 weeks vs. lomustine alone in about 280 patients. Orbus Therapeutics Inc....
BioCentury | Jul 28, 2016
Distillery Therapeutics

Therapeutics: Spermidine/spermine N1-acetyltransferase 1 (SAT1; SSAT); ornithine decarboxylase (ODC)

...to treat neuroblastoma and Phase I testing to treat gastric cancer and Type I diabetes. Orbus Therapeutics Inc....
BioCentury | Feb 25, 2016
Distillery Therapeutics

Therapeutics: Ornithine decarboxylase (ODC)

...II testing to treat neuroendocrine tumors and Phase I testing to gastric cancer and diabetes. Orbus Therapeutics Inc....
BioCentury | Aug 24, 2015
Finance

Making more music

...Jazz Pharmaceuticals plc (NASDAQ:JAZZ) are taking a new shot at the Orphan disease space with Orbus Therapeutics Inc....
BioCentury | Aug 24, 2015
Financial News

Orbus Therapeutics completes venture financing

Orbus Therapeutics Inc. , Palo Alto, Calif. Business: Cancer Date completed: 2015-08-19 Type: Venture financing Raised: $32.5 million Investors: Longitude Capital Management; H.I.G. BioVentures; Adams Street Partners; individual investor WIR Staff cancer...
BioCentury | Aug 20, 2015
Financial News

Orbus raises $32.5M series A

Orbus Therapeutics Inc. (Palo Alto, Calif.) raised $32.5 million in a series A round led by Longitude Capital, H.I.G. BioVentures and Adams Street Partners. Newly appointed Chairman Ernest Mario also participated. CEO Bob Myers told...
Items per page:
1 - 7 of 7
BioCentury | Oct 24, 2020
Finance

Oct. 23 Quick Takes: RA Capital’s $461M new fund; plus venture rounds for Sirnaomics, 3D Medicines, Zhaoke, Orbus, Araris

...and undisclosed series A investors.Orbus tops off series A, adds von Emster to boardBay Area-based Orbus Therapeutics Inc....
...btov Partners and existing investors Redalpine, VI Partners and Schroder Adveq also invested. BC Staff Araris Biotech AG Orbus Therapeutics Inc. 3D...
BioCentury | Oct 3, 2016
Clinical News

Eflornithine: Phase III started

...3-week cycle plus oral lomustine every 6 weeks vs. lomustine alone in about 280 patients. Orbus Therapeutics Inc....
BioCentury | Jul 28, 2016
Distillery Therapeutics

Therapeutics: Spermidine/spermine N1-acetyltransferase 1 (SAT1; SSAT); ornithine decarboxylase (ODC)

...to treat neuroblastoma and Phase I testing to treat gastric cancer and Type I diabetes. Orbus Therapeutics Inc....
BioCentury | Feb 25, 2016
Distillery Therapeutics

Therapeutics: Ornithine decarboxylase (ODC)

...II testing to treat neuroendocrine tumors and Phase I testing to gastric cancer and diabetes. Orbus Therapeutics Inc....
BioCentury | Aug 24, 2015
Finance

Making more music

...Jazz Pharmaceuticals plc (NASDAQ:JAZZ) are taking a new shot at the Orphan disease space with Orbus Therapeutics Inc....
BioCentury | Aug 24, 2015
Financial News

Orbus Therapeutics completes venture financing

Orbus Therapeutics Inc. , Palo Alto, Calif. Business: Cancer Date completed: 2015-08-19 Type: Venture financing Raised: $32.5 million Investors: Longitude Capital Management; H.I.G. BioVentures; Adams Street Partners; individual investor WIR Staff cancer...
BioCentury | Aug 20, 2015
Financial News

Orbus raises $32.5M series A

Orbus Therapeutics Inc. (Palo Alto, Calif.) raised $32.5 million in a series A round led by Longitude Capital, H.I.G. BioVentures and Adams Street Partners. Newly appointed Chairman Ernest Mario also participated. CEO Bob Myers told...
Items per page:
1 - 7 of 7